Patents Represented by Attorney, Agent or Law Firm David S. Harper
-
Patent number: 6703363Abstract: The present invention provides recombinant laminin 5, methods for making recombinant laminin 5, cells that express recombinant laminin 5, and methods for using the recombinant laminin 5 to accelerate wound healing, and to promote cell attachment and migration.Type: GrantFiled: April 28, 2000Date of Patent: March 9, 2004Assignee: BioStratum, Inc.Inventor: Ariel Boutaud
-
Patent number: 6671624Abstract: The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations.Type: GrantFiled: November 27, 2000Date of Patent: December 30, 2003Assignee: Cellomics, Inc.Inventors: R. Terry Dunlay, D. Lansing Taylor, Albert H. Gough, Kenneth A. Giuliano
-
Patent number: 6638907Abstract: The present invention provides substantially purified laminin 8, methods for making recombinant laminin 8, cells that express recombinant laminin 8, and methods for using the recombinant laminin 8 to accelerate the healing of injuries to vascular tissue and tissue of mesenchymal origin, and to promote cell attachment and migration.Type: GrantFiled: April 28, 2000Date of Patent: October 28, 2003Assignee: BioStratum, Inc.Inventors: Jarrko Kortesmaa, Karl Tryggvason
-
Patent number: 6632790Abstract: The present invention provides substantially purified laminin 2, methods for making recombinant laminin 2, cells that express recombinant laminin 2, and methods for using the substantially purified laminin 2 to accelerate peripheral nervous system nerve regeneration, and to promote cell attachment and migration.Type: GrantFiled: April 28, 2000Date of Patent: October 14, 2003Assignee: University of Medicine and Dentistry of New JerseyInventor: Peter Yurchenco
-
Patent number: 6620591Abstract: The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.Type: GrantFiled: April 16, 1999Date of Patent: September 16, 2003Assignee: Cellomics, Inc.Inventors: R. Terry Dunlay, D. Lansing Taylor
-
Patent number: 6610852Abstract: The present invention provides novel compounds, pharmaceutical compositions, methods, and kits for inhibiting the conversion of Amadori compounds to post Amadori advanced glycation endproducts, and for treating and preventing chronic tissue damage and diabetic complication.Type: GrantFiled: October 19, 2001Date of Patent: August 26, 2003Assignee: Kansas University Medical CenterInventors: Raja Khalifah, Aaron Ashley Booth
-
Patent number: 6579969Abstract: The present invention provides isolated nucleic acid sequences and expression vectors encoding the Goodpasture antigen binding protein (GPBP), substantially purified GPBP, antibodies against GPBP, and methods for detecting GPBP.Type: GrantFiled: February 24, 2000Date of Patent: June 17, 2003Inventor: Juan Saus
-
Patent number: 6573039Abstract: The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.Type: GrantFiled: August 29, 2000Date of Patent: June 3, 2003Assignee: Cellomics, Inc.Inventors: R. Terry Dunlay, D. Lansing Taylor
-
Patent number: 6566335Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing white blood cell survival following chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.Type: GrantFiled: November 20, 2000Date of Patent: May 20, 2003Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6548263Abstract: The present invention describes novel methods for making a substrate for selective cell patterning, and the substrates themselves, wherein the method comprises contacting reactive hydroxyl groups on the surface of a substrate with a hydroxyl-reactive bifunctional molecule to form a monolayer, and using stencils to deposit cell repulsive or cell adhesive moieties in controlled locations on the cell culture substrate. Methods comprising selective differentiation of stem cells to create tissue specific and organ-specific cell substrates, as well as the cell substrates themselves are also provided.Type: GrantFiled: March 31, 2000Date of Patent: April 15, 2003Assignee: Cellomics, Inc.Inventors: Ravi Kapur, Terri Adams
-
Patent number: 6498140Abstract: The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 &agr; chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.Type: GrantFiled: June 7, 2000Date of Patent: December 24, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Michael P. Sarras, Jr.
-
Patent number: 6498138Abstract: The present invention provides methods, improved cell culture medium and kits for accelerating the generation of tissue equivalents, and for improving the quality of tissue equivalents, by growth in the presence of angiotensinogen, AI, AI analogues, Al fragments and analogues thereof, AII, AI analogues, AII fragments and analogues thereof and/or AII AT2 type 2 receptor agonists.Type: GrantFiled: March 11, 1999Date of Patent: December 24, 2002Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6482800Abstract: The present invention provides methods and kits for increasing blood flow to isehemic tissue, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.Type: GrantFiled: September 8, 2000Date of Patent: November 19, 2002Assignee: The University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6475988Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing white blood cell survival following chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.Type: GrantFiled: May 10, 1999Date of Patent: November 5, 2002Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6472411Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.Type: GrantFiled: November 28, 2000Date of Patent: October 29, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
-
Patent number: 6472400Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.Type: GrantFiled: May 28, 1999Date of Patent: October 29, 2002Assignee: University of Kansas Medical CenterInventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
-
Patent number: 6455500Abstract: The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.Type: GrantFiled: March 8, 1999Date of Patent: September 24, 2002Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere DiZerega
-
Patent number: 6455501Abstract: Methods and compositions based on chemical analogs of angiotensin II and analogs of angiotensin II fragments useful for accelerating wound healing in mammals.Type: GrantFiled: October 27, 2000Date of Patent: September 24, 2002Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. DiZerega
-
Patent number: 6448222Abstract: The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation effects cell division, cell differentiation, and morphogenesis.Type: GrantFiled: November 28, 2000Date of Patent: September 10, 2002Assignee: University of Kansas Medical CenterInventors: Michael P. Sarras, Jr., Billy G. Hudson
-
Patent number: 6444646Abstract: Angiotensin II Type 2 receptor agonists (AT2 receptor subtype agonists) are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.Type: GrantFiled: February 14, 2000Date of Patent: September 3, 2002Assignee: University of Southern CaliforniaInventors: Kathleen Elizabeth Rodgers, Gere Stodder Dizerega